Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 17beta-n-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one
2. 745, Gg
3. Avodart
4. Gg 745
5. Gg-745
6. Gg745
7. Gi198745
1. 164656-23-9
2. Avodart
3. Avolve
4. Gg-745
5. Gi 198745
6. Gi-198745
7. Gg 745
8. Duastride
9. (1s,3as,3bs,5ar,9ar,9bs,11as)-n-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
10. Nsc-740477
11. O0j6xjn02i
12. (5alpha,17beta)-n-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
13. Alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
14. Chembl1200969
15. Chebi:521033
16. Nsc-759880
17. (1s,3as,3bs,5ar,9ar,11as)-n-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
18. (4ar,4bs,6as,7s,9as,9bs,11ar)-n-(2,5-bis(trifluoromethyl)phenyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1h-indeno[5,4-f]quinoline-7-carboxamide
19. (1s,2r,7r,10s,11s,14s,15s)-n-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide
20. Dutasteride [usan]
21. Duagen
22. 1h-indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4ar,4bs,6as,7s,9as,9bs,11ar)-
23. Avodart (tn)
24. Unii-o0j6xjn02i
25. Avidart
26. Gi198745
27. Dutasteride [usan:inn:ban]
28. Ncgc00164571-01
29. (5alpha,17beta)-n-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide
30. 1h-indeno(5,4-f)quinoline-7-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4ar,4bs,6as,7s,9as,9bs,11ar)-
31. Dutasteride- Bio-x
32. Gi-198745x
33. Dutasteride [mi]
34. Dutasteride [inn]
35. Dutasteride [jan]
36. Dutasteride [vandf]
37. Schembl5903
38. Dsstox_cid_26452
39. Dsstox_rid_81626
40. Dutasteride [mart.]
41. Dsstox_gsid_46452
42. Dutasteride [usp-rs]
43. Dutasteride [who-dd]
44. Dutasteride (jan/usp/inn)
45. Gtpl7457
46. Dtxsid8046452
47. Dutasteride, >=98% (hplc)
48. Dutasteride [orange Book]
49. Dutasteride For System Suitability
50. Jalyn Component Dutasteride
51. Bcpp000248
52. Dutasteride [ep Monograph]
53. Dutasteride [usp Monograph]
54. Bcp02344
55. Ex-a1952
56. Zinc3932831
57. Tox21_112199
58. Bdbm50340481
59. Mfcd00937869
60. Nsc740477
61. S1202
62. Dutasteride Component Of Jalyn
63. Akos015920136
64. Akos015924431
65. Bcp9000630
66. Ccg-269904
67. Cs-1542
68. Db01126
69. Gs-3565
70. Nsc 740477
71. Nsc 759880
72. N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
73. Bd164398
74. Hy-13613
75. Cas-164656-23-9
76. D5973
77. D03820
78. Ab01274774-01
79. Ab01274774_02
80. 656d239
81. A810580
82. Q424760
83. Q-201052
84. Brd-k30373883-001-02-8
85. Z1563146168
86. Dutasteride, European Pharmacopoeia (ep) Reference Standard
87. Dutasteride, United States Pharmacopeia (usp) Reference Standard
88. 4-azaandrost-1-ene-17-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-, (5a,17b)-
89. Dutasteride For System Suitability, European Pharmacopoeia (ep) Reference Standard
90. (4ar,4bs,6as,7s,9as,9bs,11ar)-n-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-1h-indeno[5,4-f]quinoline-7-carboxamide
91. (5.alpha.,17.beta.)-n-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
92. (5.alpha.,5 Bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride;avodart;
93. (5alpha,17beta)-n-{2,5-bis(trifluoromethyl)-phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
94. .alpha.,.alpha.,.alpha.,.alpha.',.alpha.',.alpha.'-hexafluoro-3-oxo-4-aza-5.alpha.-androst-1-ene-17.beta.-carboxy-2',5'-xylidide
Molecular Weight | 528.5 g/mol |
---|---|
Molecular Formula | C27H30F6N2O2 |
XLogP3 | 5.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 2 |
Exact Mass | 528.22114718 g/mol |
Monoisotopic Mass | 528.22114718 g/mol |
Topological Polar Surface Area | 58.2 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 964 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Avodart |
PubMed Health | Dutasteride (By mouth) |
Drug Classes | Benign Prostatic Hypertrophy Agent |
Drug Label | AVODART is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase, an intracellular enzyme that converts testosterone to DHT. Dutasteride is chemically designated as (5,17... |
Active Ingredient | Dutasteride |
Dosage Form | Capsule |
Route | Oral |
Strength | 0.5mg |
Market Status | Prescription |
Company | Glaxosmithkline |
2 of 4 | |
---|---|
Drug Name | Dutasteride |
PubMed Health | Dutasteride (By mouth) |
Drug Classes | Benign Prostatic Hypertrophy Agent |
Drug Label | AVODART is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase, an intracellular enzyme that converts testosterone to DHT. Dutasteride is chemically designated as (5,17... |
Active Ingredient | Dutasteride |
Dosage Form | Capsule |
Route | oral; Oral |
Strength | 0.5mg |
Market Status | Tentative Approval; Prescription |
Company | Endo Pharms; Sandoz; Banner Pharmacaps; Roxane; Barr |
3 of 4 | |
---|---|
Drug Name | Avodart |
PubMed Health | Dutasteride (By mouth) |
Drug Classes | Benign Prostatic Hypertrophy Agent |
Drug Label | AVODART is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase, an intracellular enzyme that converts testosterone to DHT. Dutasteride is chemically designated as (5,17... |
Active Ingredient | Dutasteride |
Dosage Form | Capsule |
Route | Oral |
Strength | 0.5mg |
Market Status | Prescription |
Company | Glaxosmithkline |
4 of 4 | |
---|---|
Drug Name | Dutasteride |
PubMed Health | Dutasteride (By mouth) |
Drug Classes | Benign Prostatic Hypertrophy Agent |
Drug Label | AVODART is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase, an intracellular enzyme that converts testosterone to DHT. Dutasteride is chemically designated as (5,17... |
Active Ingredient | Dutasteride |
Dosage Form | Capsule |
Route | oral; Oral |
Strength | 0.5mg |
Market Status | Tentative Approval; Prescription |
Company | Endo Pharms; Sandoz; Banner Pharmacaps; Roxane; Barr |
Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with [tamsulosin].
Dutasteride is a synthetic 4-azasteroid compound that selectively inhibits both the type I and type II isoforms of steroid 5-reductase, an intracellular enzyme that converts testosterone to 5-dihydrotestosterone (DHT). Dutasteride works by reducing the levels of circulating DHT. It was also shown to reduce the size of the prostate gland, improve urinary flow, and symptoms of benign prostatic hyperplasia alone or in combination with tamsulosin. The effect of the reduction of DHT by dutasteride is dose-dependent, with the maximum effect observed within 1-2 weeks following initial administration. After 1 and 2 weeks of daily dosing with dutasteride 0.5 mg, median serum DHT concentrations were reduced by 85% and 90%, respectively. The serum concentrations of DHT were maintained to be decreased by more than 90% in 85% of patients following 1 years' administration of oral dutasteride 0.5 mg/day. As evident from the clinical studies, dutasteride may also cause decreases in serum PSA in the presence of prostate cancer.
5-alpha Reductase Inhibitors
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE. (See all compounds classified as 5-alpha Reductase Inhibitors.)
G04CB02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
G - Genito urinary system and sex hormones
G04 - Urologicals
G04C - Drugs used in benign prostatic hypertrophy
G04CB - Testosterone-5-alpha reductase inhibitors
G04CB02 - Dutasteride
Absorption
Following oral administration of a single dose of 0.5 mg dutasteride, the peak serum concentrations were reached within 2 to 3 hours. Following daily oral administration of 0.5 mg dutasteride, the steady-state concentration of 40 ng/mL is expected to be achieved at 6 months following initial administration. In healthy subjects, the absolute bioavailability was 60%, ranging from 40% to 94%. While food intake reduced the maximum serum concentrations by 10 to 15%, food intake is reported to have a negligible effect on the bioavailability of the drug.
Route of Elimination
Dutasteride and its metabolites mainly undergo fecal excretion. About 1-15% of the dose is excreted as the unchanged parent compound, while 2-90% of the total dose is excreted in the form of dutasteride-related metabolites in the feces. Trace amounts of unchanged dutasteride, with less than 1%, can also be detected in the urine. Therefore, on average, the dose unaccounted for approximated 55%, with a range between 5% and 97%.
Volume of Distribution
Dutasteride displays a large volume of distribution ranging from 300 to 500 L. Following daily oral administration of 0.5 mg dutasteride healthy subjects for 12 months, the semen dutasteride concentrations averaged 3.4 ng/mL (range: 0.4 to 14 ng/mL) with 11.5% of serum dutasteride concentrations being partitioned into semen.
Clearance
In a study of healthy volunteers receiving single oral doses of dutasteride ranging from 0.01 to 40 mg, dutasteride displayed a low linear clearance of 0.58 L/h. The estimated inter-individual variability for the linear clearance was high.
Dutasteride undergoes extensive hepatic metabolism mediated by CYP3A4 and CYP3A5. 4-hydroxydutasteride, 6-hydroxydutasteride, 6,4-dihydroxydutasteride, 1,2-dihydrodutasteride, and 15-hydroxydutasteride metabolites are formed. 2 minor metabolites - 6,4-dihydroxydutasteride and 15-hydroxydutasteride - can also be detected. According to _in vitro_ studies, 4-hydroxydutasteride and 1,2-dihydrodutasteride mediated inhibitory actions against both isoforms of 5-reductase but with lower potency when compared to the parent drug. The activity of 6-hydroxydutasteride is comparable to that of dutasteride.
The terminal elimination half-life of dutasteride is approximately 5 weeks at steady state. This long half-life accounts for the serum concentrations remaining detectable for up to 4 to 6 months after discontinuation of treatment.
The 5-reductase is a nuclear-bound steroid intracellular enzyme primarily located in the prostatic stromal cell that converts the androgen testosterone into the more active metabolite, 5-dihydrotestosterone (DHT). DHT is considered to be the primary androgen playing a role in the initial development and subsequent enlargement of the prostate gland. It serves as the hormonal mediator for the hyperplasia upon accumulation within the prostate gland. DHT displays a higher affinity towards androgen receptors in the prostate gland compared to testosterone and by acting on the androgen receptors, DHT modulates genes that are responsible for cell proliferation. Responsible for the synthesis of approximately one-third of circulating DHT, type I 5-reductase is predominant in the sebaceous glands of most regions of skin, including the scalp, and liver. The type II 5a-reductase isozyme is primarily found in the prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT. Due to its dual inhibition of both isoenzymes of 5-reductase, dutasteride causes a near-complete suppression of DHT. Compared to a 70% reduction of serum DHT levels caused by [finasteride], a near-complete suppression of serum DHT-more than 90% is seen with dutasteride. By forming a stable complex with both type II and type II 5-reductase, dutasteride inhibits its enzymatic action of converting testosterone to 5-dihydrotestosterone (DHT), which is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. It is proposed that DHT is the principal androgen responsible for prostatic growth in later life-normal masculinization of the external genitalia and maturation of the prostate gland during development-thus reducing the serum DHT levels results in reduced prostatic volume and increased epithelial apoptosis. Dutasteride is a competitive and specific inhibitor of both Type I and Type II 5-reductase isoenzymes and when evaluated under _in vitro_ and _in vivo_ conditions, the dissociation of the drug from the drug-enzyme complex is reported to be extremely slow. Dutasteride does not bind to the human androgen receptor.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2013-08-12
Pay. Date : 2012-11-30
DMF Number : 26475
Submission : 2012-10-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24304
Submission : 2010-10-19
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14643
Submission : 1999-12-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20180
Submission : 2009-05-06
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23810
Submission : 2010-05-18
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-06-24
Pay. Date : 2021-04-02
DMF Number : 26803
Submission : 2013-01-09
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-09
Pay. Date : 2012-12-06
DMF Number : 23533
Submission : 2010-02-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23494
Submission : 2010-04-30
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24880
Submission : 2011-07-29
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-05-07
Pay. Date : 2015-04-30
DMF Number : 20918
Submission : 2007-10-08
Status : Active
Type : II
Certificate Number : CEP 2014-306 - Rev 01
Status : Valid
Issue Date : 2023-11-16
Type : Chemical
Substance Number : 2641
Certificate Number : R0-CEP 2015-050 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2017-06-15
Type : Chemical
Substance Number : 2641
Certificate Number : R1-CEP 2016-126 - Rev 00
Status : Valid
Issue Date : 2022-07-26
Type : Chemical
Substance Number : 2641
Dutasteride, Non-micronised And Micronised
Certificate Number : CEP 2020-298 - Rev 02
Status : Valid
Issue Date : 2024-12-13
Type : Chemical
Substance Number : 2641
Dutasteride, Crystalline Form-I, Micronised And ...
Certificate Number : CEP 2014-019 - Rev 01
Status : Valid
Issue Date : 2024-12-16
Type : Chemical
Substance Number : 2641
Certificate Number : R1-CEP 2015-252 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2021-01-15
Type : Chemical
Substance Number : 2641
Certificate Number : CEP 2022-172 - Rev 00
Status : Valid
Issue Date : 2025-02-17
Type : Chemical
Substance Number : 2641
Certificate Number : CEP 2015-258 - Rev 01
Status : Valid
Issue Date : 2024-02-06
Type : Chemical
Substance Number : 2641
Certificate Number : CEP 2022-503 - Rev 00
Status : Valid
Issue Date : 2025-03-18
Type : Chemical
Substance Number : 2641
Dutasteride (for manufacturing purposes only) "Apitoria"
Registration Number : 306MF10087
Registrant's Address : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad, Telangana, INDIA.
Initial Date of Registration : 2024-07-03
Latest Date of Registration : 2024-07-03
Registration Number : 306MF10133
Registrant's Address : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad, Telangana, INDIA.
Initial Date of Registration : 2024-10-10
Latest Date of Registration : 2024-10-10
Registration Number : 231MF10062
Registrant's Address : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad Telangana, India
Initial Date of Registration : 2019-03-04
Latest Date of Registration : 2019-03-04
Registration Number : 231MF10024
Registrant's Address : 7-2-A2,Hetero Corporate,Industrial Estates Sanath Nagar,Hyderabad-500 018 Telangana I...
Initial Date of Registration : 2019-02-05
Latest Date of Registration : 2019-02-05
Registration Number : 229MF10186
Registrant's Address : 7-2-A2,Hetero Corporate,Industrial Estates Sanath Nagar,Hyderabad-500 018 Telangana I...
Initial Date of Registration : 2017-10-12
Latest Date of Registration : 2017-10-12
Registration Number : 230MF10024
Registrant's Address : Plot No: C-24, Sanath Nagar Industrial Estate, Sanath Nagar, Hyderabad, Telangana, In...
Initial Date of Registration : 2018-02-14
Latest Date of Registration : 2018-02-14
Registration Number : 302MF10123
Registrant's Address : HF51, Hal-Far Industrial Estate BBG3000-Birzebbugia, Malta
Initial Date of Registration : 2020-10-05
Latest Date of Registration : 2020-10-05
Registration Number : 230MF10161
Registrant's Address : 114 Marine Chambers, 11, New Marine Lines, Mumbai-400 020, INDIA
Initial Date of Registration : 2018-12-03
Latest Date of Registration : 2019-11-15
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-15
Valid Till : 2025-06-16
Written Confirmation Number : WC-0034
Address of the Firm : Chemical Technical Operations-Unit II, Plot Nos. 1, 75A, 75B, 105, 110, 111 & 1...
Date of Issue : 2022-06-06
Valid Till : 2025-06-10
Written Confirmation Number : WC-0017
Address of the Firm : Unit No. VIII, Sy. No. 10 & 13, Gaddapotharam Village, I,D.A. Kazipally, Jinnara...
Date of Issue : 2022-09-16
Valid Till : 2025-08-08
Written Confirmation Number : WC-0041
Address of the Firm : Unit-I, Survey No.10, I.D.A, Gaddapotharam Village, Jinnaram Mandal,Medak Dist, ...
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm : Sy. Nos: 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Man...
Date of Issue : 2018-06-11
Valid Till : 2021-06-10
Written Confirmation Number : WC-0419
Address of the Firm : Plot No A-1/2 Phase III GIDC Vapi-396195 Valsad Gujarat
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Sangjin Corporation
Registration Date : 2010-12-30
Registration Number : No. 4692-3-ND
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri V...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : EQ Bio Co., Ltd.
Registration Date : 2024-10-25
Registration Number : No. 4692-3-ND(3)
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri V...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : JDW Pharmaceutical Co., Ltd.
Registration Date : 2018-08-14
Registration Number : No. 4692-3-ND(2)
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri V...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : YuYu Pharmaceutical Co., Ltd.
Registration Date : 2011-09-02
Registration Number : No. 4692-3-ND(1)
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri V...
Registrant Name : Sungjin Exim Co., Ltd.
Registration Date : 2015-07-23
Registration Number : No. 5556-5-ND
Manufacturer Name : Ind-Swift Laboratories Limit...
Manufacturer Address : Village Bhagwanpur, Barwala Road, Near Derabassi District SAS Nagar (Mohali), Punjab ...
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2011-07-28
Registration Number : Su342-5-ND
Manufacturer Name : MSN Laboratories PVT.LTD,
Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604&605, Rudraram (Village), Patancheru (Mandal), Sa...
Registrant Name : SG Biochem Co., Ltd.
Registration Date : 2016-09-29
Registration Number : Su342-5-ND(5)
Manufacturer Name : MSN Laboratories PVT.LTD
Manufacturer Address : Sy. No. 317 , 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal),...
Registrant Name : Korea United Pharmaceutical Co., Ltd.
Registration Date : 2015-12-02
Registration Number : Su342-5-ND(3)
Manufacturer Name : MSN Laboratories Private Lim...
Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), ...
Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2015-02-23
Registration Number : Su342-5-ND(2)
Manufacturer Name : MSN Laboratories Private Lim...
Manufacturer Address : Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), ...
Registrant Name : IMCD Korea Co., Ltd.
Registration Date : 2017-02-28
Registration Number : Su342-5-ND(6)
Manufacturer Name : MSN Laboratories PVT.LTD
Manufacturer Address : Sy. No. 317 , 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal),...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-076
Start Marketing Date : 2012-08-16
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65862-797
Start Marketing Date : 2023-12-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51552-1551
Start Marketing Date : 2018-02-09
End Marketing Date : 2026-02-28
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 63379-016
Start Marketing Date : 2014-05-16
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68554-0079
Start Marketing Date : 2001-11-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 38779-3086
Start Marketing Date : 2022-03-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 82393-401
Start Marketing Date : 2024-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59057-005
Start Marketing Date : 2015-04-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 64918-1031
Start Marketing Date : 2014-07-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 64918-1904
Start Marketing Date : 2019-11-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
About the Company : Gonane Pharma, is a contract pharmaceutical company located in Gujarat, India, specializing in the manufacturing and marketing of Corticosteroids, Hormones, Antivirals, and Oncolog...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
About the Company : Anwita Drugs is a technocrat-driven pharmaceutical company with over 28 years of expertise in designing and developing solid oral dosage forms (OSD), nutraceuticals, and dietary su...
About the Company : Credo Life one place for credibility, commitment, quality and delivery on time. Promoted by a dynamic team of techno-commercial professionals with decades of experience in the Phar...
About the Company : Human Pharmalabs Pvt. Ltd. was founded to manufacture lifesaving critical APIs in India, pioneering the introduction of Corticosteroid APIs. The company adheres to international st...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
64
PharmaCompass offers a list of Dutasteride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dutasteride manufacturer or Dutasteride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dutasteride manufacturer or Dutasteride supplier.
PharmaCompass also assists you with knowing the Dutasteride API Price utilized in the formulation of products. Dutasteride API Price is not always fixed or binding as the Dutasteride Price is obtained through a variety of data sources. The Dutasteride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, including repackagers and relabelers. The FDA regulates DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE supplier is an individual or a company that provides DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE active pharmaceutical ingredient (API) or DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE finished formulations upon request. The DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE suppliers may include DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE API manufacturers, exporters, distributors and traders.
click here to find a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE DMF (Drug Master File) is a document detailing the whole manufacturing process of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE active pharmaceutical ingredient (API) in detail. Different forms of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE DMFs exist exist since differing nations have different regulations, such as DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE DMF submitted to regulatory agencies in the US is known as a USDMF. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE USDMF includes data on DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE Drug Master File in Japan (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE JDMF) empowers DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE JDMF during the approval evaluation for pharmaceutical products. At the time of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE Drug Master File in Korea (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE. The MFDS reviews the DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE KDMF as part of the drug registration process and uses the information provided in the DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE KDMF to evaluate the safety and efficacy of the drug.
After submitting a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE API can apply through the Korea Drug Master File (KDMF).
click here to find a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE suppliers with KDMF on PharmaCompass.
A DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CEP of the European Pharmacopoeia monograph is often referred to as a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE Certificate of Suitability (COS). The purpose of a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE to their clients by showing that a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CEP has been issued for it. The manufacturer submits a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CEP (COS) as part of the market authorization procedure, and it takes on the role of a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CEP holder for the record. Additionally, the data presented in the DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE DMF.
A DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE suppliers with CEP (COS) on PharmaCompass.
A DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE written confirmation (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE WC) is an official document issued by a regulatory agency to a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE manufacturer, verifying that the manufacturing facility of a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE APIs or DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE finished pharmaceutical products to another nation, regulatory agencies frequently require a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE WC (written confirmation) as part of the regulatory process.
click here to find a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE suppliers with NDC on PharmaCompass.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE GMP manufacturer or DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE GMP API supplier for your needs.
A DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CoA (Certificate of Analysis) is a formal document that attests to DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE's compliance with DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE specifications and serves as a tool for batch-level quality control.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CoA mostly includes findings from lab analyses of a specific batch. For each DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE may be tested according to a variety of international standards, such as European Pharmacopoeia (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE EP), DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE USP).